Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

Home > MTN-001

MTN-001

Details
Protocol Title: 
Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir
DAIDS Protocol ID: 
10617
Status: 
Participants off Study and Primary Analysis Completed

Protocol Chair(s)

Craig Hendrix [1] (Protocol Chair)

Email Groups

MTN-001 Accrual [2]
MTN-001 Investigators [3]
MTN-001 Pharmacists [4]
MTN-001 Protocol Deviations Team [5]
MTN-001 Protocol Safety Review Team [6]
MTN-001 Protocol Team [7]
MTN-001 Pub Committee [8]
MTN-001 Safety Reports [9]
MTN-001 Study Coordinators [10]
MTN-001 Study Management Team [11]
MTN-001 Study Monitoring Committee [12]
Sites
Bronx-Lebanon Hospital Center [13]
Pitt CRS [14]
University of Alabama at Birmingham [15]
Case Western Reserve University / University Hospitals Case Medical Center [16]
Bothas Hill Clinical Research Site [17]
Umkomaas Clinical Research Site [18]
Makerere University - Johns Hopkins University Research Collaboration [19]
Countries
South Africa [20]
United States [21]
Uganda [22]
Description
Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir

MTN-001 is a Phase II trial directly comparing the oral tablet and vaginal gel formulations of the antiretroviral (ARV) drug tenofovir. Specifically, MTN-001 is evaluating women’s adherence to and acceptance of three daily regimens – tenofovir gel, tenofovir tablet and the two taken together – and the pharmacokinetics of each approach. Pharmacokinetic studies are conducted to learn how a particular drug is absorbed by and distributed in the body over time. Researchers will enroll 144 sexually active HIV-negative women at sites in Uganda, South Africa and the United States, who at the end of the 21-week study will have followed each regimen for six weeks, with one week between when no study product is used. The 72 women enrolled at the two U.S. sites will be involved in more intensive assessments of each approach.

Other Study Info
Sponsors:
Division of AIDS, US National Institute of Allergy and Infectious Diseases
 
US National Institutes of Health
 
Co-Sponsors:
CONRAD, Gilead Sciences, Inc.
 
Study design:
Phase 2, multi-site, randomized, six sequence, three period, open label crossover study
Printer-friendly version [23]
Source URL: http://www.mtnstopshiv.org/studies/71

Links:
[1] http://www.mtnstopshiv.org/users/chendrix
[2] http://www.mtnstopshiv.org/people/emailgroups/77
[3] http://www.mtnstopshiv.org/people/emailgroups/61
[4] http://www.mtnstopshiv.org/people/emailgroups/113
[5] http://www.mtnstopshiv.org/people/emailgroups/57
[6] http://www.mtnstopshiv.org/people/emailgroups/58
[7] http://www.mtnstopshiv.org/people/emailgroups/56
[8] http://www.mtnstopshiv.org/people/emailgroups/133
[9] http://www.mtnstopshiv.org/people/emailgroups/65
[10] http://www.mtnstopshiv.org/people/emailgroups/59
[11] http://www.mtnstopshiv.org/people/emailgroups/60
[12] http://www.mtnstopshiv.org/people/emailgroups/91
[13] http://www.mtnstopshiv.org/sites/49
[14] http://www.mtnstopshiv.org/sites/51
[15] http://www.mtnstopshiv.org/sites/53
[16] http://www.mtnstopshiv.org/sites/59
[17] http://www.mtnstopshiv.org/sites/50
[18] http://www.mtnstopshiv.org/sites/52
[19] http://www.mtnstopshiv.org/sites/60
[20] http://www.mtnstopshiv.org/node/3558
[21] http://www.mtnstopshiv.org/countries/united-states
[22] http://www.mtnstopshiv.org/countries/uganda
[23] http://www.mtnstopshiv.org/print/71

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu